ESTRO 35 2016 S721 ________________________________________________________________________________ gantry speed GS) and T3 (variation of MLC Speed MLCS) were updated. Even so, we decided to redraw completely T2 and T3, in the respect of the effective main concept. A family of new plans was generated to guarantee flexibility in the QA procedure and to support the user in a possible troubleshooting.
Results:
First version of the test T2 and T3, have presented during time differences respect reference value>2% (always<3%), for Clinac iX and Unique, while TrueBeam data were always <2%. The first T2 band presents a systematically higher value respect the others, explainable with some weakness in the test itself. Vs2 of T2 and T3, showed an agreement well below 2% for all the three linacs, but still with a systematic higher value for the T2 first delivered strip. The delineation of the new package of RT-plans started from the tune of number and width of the strips; the best compromise was found with 5 strip of 2.8 cm. Now T2 and T3 are fully compatible and can be superimposed, running also a T3 with the same DR-GS variation presents in T2. From this main plan version of T2 and T3, the new family of rt-plans allows to perform tests changing arc direction or/and MLC direction, while an additional basic editing of the dicom files allows to vary the main delivery parameters, in addition to order of the delivered combinations, arc range, MU/deg, etc, as independently as possible.
Conclusion:
The new package of RT-plans is proposed in the fully respect of the original idea by Ling, with the intent to offer a more effective tool adjustable to single centre characters. Of particular interested is the extension to FFF beams, which are widely used in stereotactic regimes. .0, and PTV55.5,respectively. All SIB-VMAT plans were optimized using the "dual-arc" feature with 6MV photon energy. The differences in dose distribution for all PTVs and organ-at-risk were assessed using different metrics (D95%= dose to 95% of PTV, D98%= near-minimum, Dmean= mean dose, V95%= volume receiving al least 95% of prescribed dose, D2%=near-maximum dose). The PTV70.5 was also separated into components in tissue (PTVtiss) and air (PTVair). Collapsed Cone plans were also renormalized (CCCr) in order to obtain the same target coverage in terms of D95% of PBC calculation.
EP
Results: PBC algorithm overestimated dose to PTVs for all considered metrics. The averaged Dmean and D95% to PTV70.5 calculated by CCC decreased by 1.8% (range:0.9%-2.8%) and 3.1% (range:1.5%-5.3%), respectively (1.5% and 2.8% lower for PTVtiss, and 5.5% and 8.6% lower for PTVair). Averaged D98% to PTV70.5 decreased by 3.4% (2.4% in tissue and 9.4% in air). Averaged V95% decreased from 96.0% to 90.2% (from 96.1% to 91.2% for PTVtiss, and from 96.0% to 70.9% for PTVair). The magnitude of dose differences are strongly correlated with the amount of air cavities in PTV70.5. A similar trend was observed for PTV60 and PTV55.5. Maximum doses to spine and brainstem PRVs were found to be approximately 1 Gy lower with CCC. The Dmean to pharyngeal constrictors muscles was found 4.7% higher with PBC. No differences were observed for parotids and mandible. PBC slightly underestimated the doses to eyes and lens (but ≤ 0.5 Gy). When the dose calculation were performed in water, the two algorithms provided differences in dose distributions <0.5%.
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Conclusion: The CCC algorithm should be used in preference to PBC in VMAT treatments of nasopharyngeal tumors. A key question remains open: should the prescription dose be adjusted to the actually delivered dose, more accurately predicted by CCC algorithm? If radiation oncologists wanted to keep the PBC original dose prescription and the same accepting criteria for target coverage when switching from PBC to CCC, up to 5% more radiation doses would be given. To verify the accuracy of planned dose distribution for patient treatment, patient dose quality assurance using the solid water equivalent phantom is usually performed. This method, however, is not the method of verifying the absorbed dose in real patient. In this study, as a previous process of developing dose calculation algorithm in human, we measured the transit dose using the radiophotoluminescence glass rod detector to develop dose calculation algorithm in homogeneous phantom.
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Material and Methods:
We measured the trasit dose at 150cm from source of linear accelerator to calculate the dose in the homogeneous phantom. The homogeneous phantom (10cm, 20cm, 30cm thickness) was located nearby the isocenter. We can calculate the dose at the bottom of phantom using the measured transit dose, inverse square law value and scatter factor. Scatter factor in this algorithm is ratio of scatter at the bottom of phantom and scatter at the measurement point of transit dose. To develop dose calculation algorithm in homogeneous phantom, we measured the field size dependence of transit dose and bottom dose to calculate the scatter factor, the relative dose response to correct the change of field size and location of isocenter. We evaluated the algorithm of 6MV X-ray beam in 10cm x 10cm field, 200MU.
Results:
The measurement results of the relative dose response for isocenter location change are increased when the SSD decreases. The measured scatter factor was about 1.35 in all cases. We could calculate the dose in the phantom using the transit dose, inverse square law, scatter factor and percentage depth dose data. We evaluated the accuracy of developed phantom-dose calculation algorithm. The accuracies of 10cm, 20cm and 30cm phantom were 0.54%, 1.03% and -1.65%, respectively.
Conclusion:
We developed the phantom-dose calculation algorithm using the transit dose, inverse square law, scatter factor and PDD data. This result would be used in the development of dose calculation algorithm in the inhomogeneous phantom and real patient.
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